Does High-Sensitivity Cardiac Troponin T (hs-cTnT) measurement predict all-cause mortality in cancer patients before starting chemotherapy?
Baseline hs-cTnT measurement (using a cutoff of 7 ng/L) is an effective tool to stratify mortality risk in cancer patients prior to chemotherapy.
Based on our non-selected cohort of cardio-oncological patients, hs-cTnT was able to identify patients with high mortality by using a low cutoff of 7 ng/L. We conclude that measurement of hs-cTnT is an important tool to stratify the risk for mortality of cancer patients before starting chemotherapy.
Finke et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: